Loading...
Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
Trigo, J. Cho, B. C. Park, K. Girard, N. Viteri, S. Garrido, P. Krebs, Matthew G Thayu, M. Knoblauch, R. E. Xie, J.
Trigo, J.
Cho, B. C.
Park, K.
Girard, N.
Viteri, S.
Garrido, P.
Krebs, Matthew G
Thayu, M.
Knoblauch, R. E.
Xie, J.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Trigo J, Cho BC, Park K, Girard N, Viteri S, Garrido P, et al. 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC). Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S38–9.